Go to Bing homepage

HERTFORDSHIRE, England and PITTSBURGH, Feb. 22, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. MYL, -1.77% today announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, ...

Mylan N.V. MYL is scheduled to report fourth-quarter 2018 results on Feb 26, after the market closes. The company’s performan...

Mylan N.V. (NASDAQ:MYL) has launched Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, a generic version of Indivior's Suboxone Sublingual Film in U.S., for the treatment of ...

Your article was successfully shared with the contacts you provided. Kathleen O’Malley, United States Court of Appeals for th...

The therapies, from Mylan and Dr. Reddy’s Laboratories, are generic equivalents of Indivior PLC’s Suboxone sublingual film. 1 ...

(Reuters) - Mylan NV on Tuesday priced its generic version of GlaxoSmithKline’s blockbuster asthma treatment Advair 70 percent lower than the branded medicine. The treatment, the first generic of Adva...

Law360 (February 20, 2019, 8:23 PM EST) -- The Federal Circuit has disqualified Katten Muchin Rosenman LLP from representing Mylan in patent cases brought by units of Valeant Pharmaceuticals, ruling t...

Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...

Mylan’s recently FDA-approved Advair Diskus generic to be offered at 70% cost reduction to its reference drug, and 67% less t...

The market research report is a perfect tool for digging deep into critical aspects of the global Divalproex Sodium market an...

Mylan (NSDQ:MYL) said today that it launched its buprenorphine and naloxone sublingual film as a generic of Indivior‘s (LON:I...

Law360 (February 19, 2019, 4:16 PM EST) -- The U.S. Supreme Court on Tuesday said it wouldn't review the Federal Circuit’s decision to uphold a UCB Inc. patent covering the epilepsy drug Vimpat, despi...